Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5L0B

Crystal Structure of Autotaxin and Compound 1

Summary for 5L0B
Entry DOI10.2210/pdb5l0b/pdb
Related5L0E 5L0K
DescriptorEctonucleotide pyrophosphatase/phosphodiesterase family member 2, alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (8 entities in total)
Functional Keywordsphospholipase, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceRattus norvegicus (Rat)
Total number of polymer chains2
Total formula weight204063.62
Authors
Durbin, J.D. (deposition date: 2016-07-27, release date: 2016-08-10, Last modification date: 2024-10-30)
Primary citationJones, S.B.,Pfeifer, L.A.,Bleisch, T.J.,Beauchamp, T.J.,Durbin, J.D.,Klimkowski, V.J.,Hughes, N.E.,Rito, C.J.,Dao, Y.,Gruber, J.M.,Bui, H.,Chambers, M.G.,Chandrasekhar, S.,Lin, C.,McCann, D.J.,Mudra, D.R.,Oskins, J.L.,Swearingen, C.A.,Thirunavukkarasu, K.,Norman, B.H.
Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.
Acs Med.Chem.Lett., 7:857-861, 2016
Cited by
PubMed Abstract: In an effort to develop a novel therapeutic agent aimed at addressing the unmet need of patients with osteoarthritis pain, we set out to develop an inhibitor for autotaxin with excellent potency and physical properties to allow for the clinical investigation of autotaxin-induced nociceptive and neuropathic pain. An initial hit identification campaign led to an aminopyrimidine series with an autotaxin IC50 of 500 nM. X-ray crystallography enabled the optimization to a lead compound that demonstrated favorable potency (IC50 = 2 nM), PK properties, and a robust PK/PD relationship.
PubMed: 27660691
DOI: 10.1021/acsmedchemlett.6b00207
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.41 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon